An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction.
Aviv A, Shelef A, Weizman A.
Aviv A, et al. Among authors: weizman a.
J Clin Psychiatry. 2004 Jan;65(1):97-103. doi: 10.4088/jcp.v65n0117.
J Clin Psychiatry. 2004.
PMID: 14744177
Clinical Trial.
The effect on sexual function was assessed by the International Index of Erectile Function and the Valevski-Weizman Male Sexual Function scale. RESULTS: Nine (75%) of the 12 patients completed the 6-week trial, and 3 patients (25%) stopped taking sildenafil after 3 weeks d …
The effect on sexual function was assessed by the International Index of Erectile Function and the Valevski-Weizman Male Sexual Funct …